Heidy King-Jones Biography and Net Worth

Chief Legal Officer and Corporate Secretary of Spyre Therapeutics


Heidy King-Jones, J.D., LL.M., is Chief Legal Officer and Corporate Secretary. Ms. King-Jones most recently served as the Chief Legal Officer and Corporate Secretary at Provention Bio, Inc., where she led through various financings, the approval of TZIELD®, the company’s successful transition from clinical-stage to commercial-stage as well as its acquisition by Sanofi in April 2023. Prior to her leadership role at Provention Bio, she was a Senior Vice President, General Counsel and Corporate Secretary at Axcella Health Inc. where she was responsible for Axcella’s corporate legal function and strategy. From 2013 to 2018, she held positions of increasing responsibility in the legal department at Sarepta Therapeutics, Inc., including overseeing all Corporate Law matters as Senior Director, Corporate Law. While at Sarepta, she served as a member of the company’s commercial readiness working group and was responsible for the development of the compliance program, contract and other legal work for the launch of its first product, Exondys 51®. Ms. King-Jones began her legal career in the Securities & Public Companies Practice Group at Ropes & Gray LLP, where she represented private and publicly traded companies in the pharmaceutical, utility, and technology industries. She holds a J.D. and LL.M. in International and Comparative Law from Cornell Law School, and a B.A. from Dartmouth College.

What is Heidy King-Jones' net worth?

The estimated net worth of Heidy King-Jones is at least $258.30 thousand as of September 1st, 2026. Ms. King-Jones owns 2,845 shares of Spyre Therapeutics stock worth more than $258,298 as of September 9th. This net worth evaluation does not reflect any other assets that Ms. King-Jones may own. Learn More about Heidy King-Jones' net worth.

How do I contact Heidy King-Jones?

The corporate mailing address for Ms. King-Jones and other Spyre Therapeutics executives is 805 Las Cimas Parkway, Suite 100, Austin, TX 78746, United States. Spyre Therapeutics can also be reached via phone at 512-942-2935 and via email at [email protected]. Learn More on Heidy King-Jones' contact information.

Has Heidy King-Jones been buying or selling shares of Spyre Therapeutics?

During the last ninety days, Heidy King-Jones has sold $2,480,592.69 in shares of Spyre Therapeutics stock. Most recently, Heidy King-Jones sold 400 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $90.00, for a transaction totalling $36,000.00. Following the completion of the sale, the insider now directly owns 2,845 shares of the company's stock, valued at $256,050. Learn More on Heidy King-Jones' trading history.

Who are Spyre Therapeutics' active insiders?

Spyre Therapeutics' insider roster includes Jeffrey Albers (Director), Scott Burrows (CFO), Michael Henderson (Director), Heidy King-Jones (Chief Legal Officer and Corporate Secretary), Sheldon Sloan (Chief Medical Officer), and Cameron Turtle (CEO). Learn More on Spyre Therapeutics' active insiders.

Are insiders buying or selling shares of Spyre Therapeutics?

In the last twelve months, insiders at the sold shares 31 times. They sold a total of 5,219,870 shares worth more than $436,706,965.30. The most recent insider tranaction occured on September, 2nd when insider Heidy King-Jones sold 400 shares worth more than $36,000.00. Insiders at Spyre Therapeutics own 15.7% of the company. Learn More about insider trades at Spyre Therapeutics.

Information on this page was last updated on 9/2/2026.

Heidy King-Jones Insider Trading History at Spyre Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/2/2026Sell400$90.00$36,000.002,845View SEC Filing Icon  
9/1/2026Sell27,999$87.31$2,444,592.692,845View SEC Filing Icon  
See Full Table

Heidy King-Jones Buying and Selling Activity at Spyre Therapeutics

This chart shows Heidy King-Jones's buying and selling at Spyre Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Spyre Therapeutics Company Overview

Spyre Therapeutics logo
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $90.79
Low: $85.00
High: $92.10

50 Day Range

MA: $98.07
Low: $86.63
High: $108.92

2 Week Range

Now: $90.79
Low: $14.51
High: $110.18

Volume

1,248,755 shs

Average Volume

1,066,135 shs

Market Capitalization

$7.98 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.99